HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

[1]  Karen Billeci,et al.  Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling* , 2005, Journal of Biological Chemistry.

[2]  M. Smyth,et al.  TRAIL and its receptors as targets for cancer therapy , 2004, Cancer science.

[3]  D. Buchsbaum,et al.  Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells , 2004, Gene Therapy.

[4]  H. Kalthoff,et al.  Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells , 2003, British Journal of Cancer.

[5]  M. Herlyn,et al.  Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  S. Shankar,et al.  Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. , 2003, Cancer research.

[7]  William E Grizzle,et al.  Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  S. Ray,et al.  Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. , 2003, Cancer research.

[9]  A. Evdokiou,et al.  Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy , 2003, British Journal of Cancer.

[10]  P. Elliott,et al.  The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. , 2003, Blood.

[11]  Y. Jang,et al.  Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities. , 2003, Cancer letters.

[12]  M. MacFarlane.  TRAIL-induced signalling and apoptosis. , 2003, Toxicology letters.

[13]  R. Kimberly,et al.  Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway , 2003, Oncogene.

[14]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[15]  T. Asano,et al.  Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. , 2003, Cancer research.

[16]  H. Naganuma,et al.  A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents , 2003, British Journal of Cancer.

[17]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[18]  Y. Rustum,et al.  Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. , 2002, Cancer research.

[19]  M. Kaminishi,et al.  Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. , 2002, International journal of oncology.

[20]  E. Borden,et al.  IFN-β Pretreatment Sensitizes Human Melanoma Cells to TRAIL/Apo2 Ligand-Induced Apoptosis1 , 2002, The Journal of Immunology.

[21]  V. Shankar,et al.  Therapeutic applications of monoclonal antibodies , 2011 .

[22]  A. Evdokiou,et al.  Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis , 2002, International journal of cancer.

[23]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[24]  A. Evdokiou,et al.  Enhanced Apoptosis of Soft Tissue Sarcoma Cells with Chemotherapy: A Potential New Approach Using Trail , 2001, Journal of orthopaedic surgery.

[25]  T. Burns,et al.  Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. , 2001, The Journal of biological chemistry.

[26]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[27]  P. Hersey,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. , 2001, Cancer research.

[28]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[29]  H. Koeppen,et al.  Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 , 2001, The Journal of Immunology.

[30]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[31]  R. K Srivastava.  TRAIL/Apo-2L: mechanisms and clinical applications in cancer. , 2001, Neoplasia.

[32]  K. Bhalla,et al.  Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. , 2001, Cancer research.

[33]  J. Tschopp,et al.  The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation* , 2000, The Journal of Biological Chemistry.

[34]  K. Shiraki,et al.  Chemotherapeutic Agents Augment TRAIL‐Induced Apoptosis in Human Hepatocellular Carcinoma Cell Lines , 2000, Hepatology.

[35]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[36]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[37]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  B. Gliniak,et al.  Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. , 1999, Cancer research.

[39]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[40]  C. Smith,et al.  Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.

[41]  M. Nau,et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. , 1999, Cancer research.

[42]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[43]  Y G Meng,et al.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. , 1999, The Journal of pharmacology and experimental therapeutics.

[44]  T. Luger,et al.  Interleukin-1 Protects Transformed Keratinocytes from Tumor Necrosis Factor-related Apoptosis-inducing Ligand* , 1998, The Journal of Biological Chemistry.

[45]  T. Taniguchi,et al.  Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. , 1997, Immunity.

[46]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[47]  Tristan J. Vaughan,et al.  Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library , 1996, Nature Biotechnology.

[48]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[49]  E. Padlan,et al.  Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. , 1995, Hybridoma.

[50]  K. Yeo,et al.  Characterization of cell lines established from human hepatocellular carcinoma , 1995, International journal of cancer.

[51]  H R Hoogenboom,et al.  By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.

[52]  Klaus Rajewsky,et al.  The half‐lives of serum immunoglobulins in adult mice , 1988, European journal of immunology.

[53]  R. R. Levine.  Pharmacology: Drug Actions and Reactions , 1983 .